Drug Profile


Alternative Names: Lamivudine/zidovudine/nevirapine; Nevirapine/lamivudine/zidovudine; Nevirapine/zidovudine/lamivudine; Zidovudine/lamivudine/nevirapine; Zidovudine/nevirapine/lamivudine

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duquesne University
  • Developer Elim Pediatric Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 01 Jun 2013 Lamivudine/nevirapine/zidovudine may be available for partnering.
  • 01 Sep 2012 The US FDA informs Elim Pediatric Pharmaceuticals that it should submit separate New Drug Applications under the 505(b) pathway for the tablet and granule formulations of lamivudine/nevirapine/zidovudine
  • 30 Apr 2012 Elim Pediatric Pharmaceuticals completes a phase I trial in healthy volunteers in Nigeria (NCT01469520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top